Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 4 minute read Pharma Industry News Kashiv BioSciences bets on Latin America with Cristália deal for Xolair biosimilar Kashiv BioSciences partners with Brazil’s Cristália to commercialize omalizumab biosimilar ADL-018 in Latin America, targeting a $140M market opportunity. byPallavi MadhirajuSeptember 14, 2025